The goals of the Cytokine Core Facility of the CWRU CFAR are to provide members of the CFAR and CWRU research community access to the most modern techniques and expertise for measurement of cytokines, and to develop, test and apply novel methods for detection of cytokines and cytokine producing cells. Cytokines are critical mediators of the host response to infectious pathogens such as HIV-1 and M. tuberculosis, and cytokine biology is an essential component of much of the multidisciplinary AIDS research at CWRU. Studies range from investigations of cytokine dysregulation in HIV-1 and mycobacterial infection to cytokine immunotherapy and to determination of the roles of cytokines in host defense to HIV-1 and the opportunistic pathogens of advanced HIV-1 disease. The primary site of the Cytokine Core Facility is a dedicated 350 square foot laboratory in the biomedical research building (BRB) at CWRU. In addition, close interaction with the ACTG Immunology Advanced Technology Laboratory (ATL) and the Tuberculosis Research Unit (TBRU) at CWRU extend both the technical scope and capabilities of the cytokine core. The Cytokine Core Facility is unique and has no overlap with other core facilities at CWRU. The Cytokine Core has been critical to the following NIH-funded projects: Tuberculosis prevention and control (AI-43244, J.J. Ellner); A human model of protective immunity (AI-35207, J.J. Ellner); Heterogeneity of T cells in Mtb infection (AI-27243, W.H. Boom); Immunosuppression in mycobacterial disease (AI-18471, Z. Toossi); Expression of TB in the lung (HL-51630, E.A. Rich); Interaction of M tb. and HIV in the lung (HL-51536, Z. Toossi).

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI036219-09
Application #
6485955
Study Section
Project Start
2001-04-01
Project End
2002-03-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
9
Fiscal Year
2001
Total Cost
$196,218
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Llewellyn, George N; Alvarez-Carbonell, David; Chateau, Morgan et al. (2018) HIV-1 infection of microglial cells in a reconstituted humanized mouse model and identification of compounds that selectively reverse HIV latency. J Neurovirol 24:192-203
Longenecker, Chris T; Sullivan, Claire E; Morrison, Justin et al. (2018) The effects of HIV and smoking on aortic and splenic inflammation. AIDS 32:89-94
Tomas, Myreen E; Mana, Thriveen S C; Wilson, Brigid M et al. (2018) Tapering Courses of Oral Vancomycin Induce Persistent Disruption of the Microbiota That Provide Colonization Resistance to Clostridium difficile and Vancomycin-Resistant Enterococci in Mice. Antimicrob Agents Chemother 62:
Yanik, Elizabeth L; Hernández-Ramírez, Raúl U; Qin, Li et al. (2018) Brief Report: Cutaneous Melanoma Risk Among People With HIV in the United States and Canada. J Acquir Immune Defic Syndr 78:499-504
Sahmoudi, Karima; Abbassi, Hassan; Bouklata, Nada et al. (2018) Immune activation and regulatory T cells in Mycobacterium tuberculosis infected lymph nodes. BMC Immunol 19:33
Webel, Allison R; Moore, Shirley M; Longenecker, Chris T et al. (2018) Randomized Controlled Trial of the SystemCHANGE Intervention on Behaviors Related to Cardiovascular Risk in HIV+ Adults. J Acquir Immune Defic Syndr 78:23-33
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Eckard, Allison Ross; O'Riordan, Mary Ann; Rosebush, Julia C et al. (2018) Vitamin D supplementation decreases immune activation and exhaustion in HIV-1-infected youth. Antivir Ther 23:315-324
Webel, Allison R; Perazzo, Joseph; Longenecker, Christopher T et al. (2018) The Influence of Exercise on Cardiovascular Health in Sedentary Adults With Human Immunodeficiency Virus. J Cardiovasc Nurs 33:239-247
Yan, Junpeng; Shun, Ming-Chieh; Hao, Caili et al. (2018) HIV-1 Vpr Reprograms CLR4DCAF1 E3 Ubiquitin Ligase to Antagonize Exonuclease 1-Mediated Restriction of HIV-1 Infection. MBio 9:

Showing the most recent 10 out of 539 publications